Christine Le Bec joined Sensorion Pharma in early 2020
as Head of CMC Gene Therapy. She is responsible for all CMC
activities, including pre-clinical development, CMC transfer to
CMOS, manufacturing and supplying of Phase 1 and 2 clinical
trails. Before joining Sensorion Pharma, she worked for more
than 20 years at Genethon in the field of Gene Therapy vectors
(AAV, Lentivirus, Baculovirus) for rare diseases. She has a strong
expertise in the development, qualification, validation of analytical methods for product characterization, release testing of
gene therapy products and in stability studies. She has also a solid
knowledge of International regulations and reviewing CMC documents for clinical trial applications.
